The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I clinical trial investigating the safety, tolerability, and pharmacokinetics of HX301 (narazaciclib), a novel multi-kinase inhibitor targeting CSF1R, CDK 4/6, and ARK5, in patients with advanced solid tumors.
 
Jiani Wang
No Relationships to Disclose
 
Yehui Shi
No Relationships to Disclose
 
Suxia Luo
Consulting or Advisory Role - KYM Biosciences
 
Qing Li
No Relationships to Disclose
 
Faming Zhang
Stock and Other Ownership Interests - Hangzhou Hanx Biopharmaceuticals, Ltd.; Waterstone Pharma
Patents, Royalties, Other Intellectual Property - Hangzhou Hanx Biopharmaceuticals, Ltd.; Waterstone Pharma
 
Lei Zhang
Employment - HanX Biopharmaceuticals; Tristone Biomed Consulting
Leadership - HanX Biopharmaceuticals
Stock and Other Ownership Interests - HanX Biopharmaceuticals
 
Peng Sun
Employment - Hangzhou Hanx Biopharmaceuticals, Ltd.
Honoraria - Hangzhou Hanx Biopharmaceuticals, Ltd.
 
Yunlong Mo
Employment - Hangzhou Hanx Biopharmaceuticals, Ltd.
Travel, Accommodations, Expenses - Hangzhou Hanx Biopharmaceuticals, Ltd.
 
Ting Yu
Employment - Hangzhou Hanx Biopharmaceuticals, Ltd.
Travel, Accommodations, Expenses - Hangzhou Hanx Biopharmaceuticals, Ltd.
 
Binghe Xu
Consulting or Advisory Role - AstraZeneca; Novartis
Speakers' Bureau - AstraZeneca; Novartis